NCT03546634View on ClinicalTrials.gov

Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

June 5, 2019

Study Completion Date

January 15, 2020

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Sabin IPV

We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.

Trial Locations (1)

Unknown

Shandong Center for Disease Control and Prevention, Jinan

All Listed Sponsors
collaborator

Shandong Province Centers for Disease Control and Prevention

OTHER

lead

Centers for Disease Control and Prevention, China

OTHER_GOV

NCT03546634 - Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China | Biotech Hunter | Biotech Hunter